DAVIS, Calif.--(BUSINESS WIRE)--Apr. 17, 2018--
Arcadia
Biosciences (Nasdaq: RKDA), an agricultural food ingredient company,
today announced plans to add its new reduced gluten (RG) wheat lines to
its GoodWheat™ portfolio of branded ingredients. The company expects to
have its first RG bread wheat flour available for commercial testing by
the end of the year.

Arcadia’s reduced gluten wheat, developed through research funded in
part by a grant from the U.S. National Institutes of Health’s Diabetes
and Digestive and Kidney Disorders Institute, is the second product to
be added to Arcadia’s recently announced GoodWheat™ branded ingredients
platform, along with its high fiber Resistant Starch (RS) wheat lines.
The goal of the GoodWheat™ brand is to add value to the entire wheat
supply chain, from seed to table, by enabling a wider range of choices
to meet evolving consumer demands.

Arcadia developed RG GoodWheat™ for people who enjoy the taste, texture
and nutritional benefits of wheat in the foods they love and, at the
same time, would like to reduce gluten in their diets. The gluten-free
food market is estimated to grow to $7.59 billion by 2020 in the United
States. However, only about 1 percent of the population suffers from
celiac disease, which necessitates a gluten-free diet. A much larger
number of people who choose to eat gluten-free products do not have
gluten-related medical conditions but report feeling better by consuming
less gluten.

Arcadia’s RG product is a non-GM, patent-pending, identity preserved
specialty wheat in which allergenic glutens have been reduced by 75
percent and overall gluten content has been reduced by 60 percent. At
the same time, the levels of glutens important for bread-making are not
changed.

“A growing number of consumers are making a conscious effort to reduce
gluten in their diets, even if they haven’t been diagnosed with celiac
disease, so we developed Reduced Gluten GoodWheat™ to give those
consumers more choices to continue enjoying the healthy wheat-based
foods they love,” said Raj Ketkar, president and CEO of Arcadia
Biosciences. “These proprietary wheat varieties, developed using
advanced screening and plant breeding techniques, also give food
processors an opportunity to differentiate their brands and create
unique brand extensions.”

Arcadia expects to have its first RG GoodWheat™ branded bread wheat
flour available to test milling and baking ability in late 2018, with a
projected launch for pre-commercial activities approximately 12 months
later. Development work is also ongoing as Arcadia conducts studies into
reducing allergenic gluten levels in pasta wheat.

About Arcadia Biosciences, Inc.

Arcadia Biosciences (Nasdaq: RKDA) develops and markets high-value food
ingredients and nutritional oils that help meet consumer demand for a
healthier diet. Arcadia’s GoodWheat™ branded ingredients deliver health
benefits to consumers and enable consumer packaged goods companies to
differentiate their brands in the marketplace. The company’s portfolio
of agricultural traits are being developed to enable farmers around the
world to be more productive and minimize the impact of agriculture on
the environment. For more information visit www.arcadiabio.com.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the company’s expectations regarding
when commercial testing and pre-commercial activities will begin for its
reduced gluten bread wheat flour. Forward-looking statements are subject
to risks and uncertainties that could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties include,
but are not limited to: the company’s and its partners’ and affiliates’
ability to identify and isolate desired traits; the company’s and its
partners’ ability to develop commercial products incorporating its
traits and complete the regulatory review process for such products; the
company’s compliance with laws and regulations that impact the company’s
business, and changes to such laws and regulations; the company’s future
capital requirements and ability to satisfy its capital needs; and the
other risks set forth in the company’s filings with the Securities and
Exchange Commission from time to time, including the risks set forth in
the company’s Annual Report on Form 10-K for the year ended December 31,
2017. These forward-looking statements speak only as of the date hereof,
and Arcadia Biosciences, Inc. disclaims any obligation to update these
forward-looking statements.